[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 212
6. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chêne G: Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS; 2009 Aug 24;23(13):1743-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
  • OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART).
  • RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes.
  • Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths.
  • For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%).
  • Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression.
  • No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA.
  • CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / mortality. Adolescent. Adult. Aged. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cardiovascular Diseases / complications. Cardiovascular Diseases / immunology. Cardiovascular Diseases / mortality. Epidemiologic Methods. Female. Humans. Immune Tolerance. Liver Diseases / complications. Liver Diseases / immunology. Liver Diseases / mortality. Male. Middle Aged. Neoplasms / complications. Neoplasms / immunology. Neoplasms / mortality. Young Adult


7. Sampaio J, Brites C, Araujo I, Bacchi CE, Dittmer DP, Tanaka PY, Harrington W Jr, Netto EM: AIDS related malignancies in Brazil. Curr Opin Oncol; 2007 Sep;19(5):476-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related malignancies in Brazil.
  • PURPOSE OF REVIEW: There have been relatively few studies of HIV-related malignancies in Brazil.
  • Universal access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS.
  • Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system.
  • This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
  • In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US.
  • SUMMARY: The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2005 Oct;19 Suppl 4:S27-30 [16249650.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S133-4 [16619688.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):719-23 [16628586.001]
  • [Cites] Braz J Med Biol Res. 2006 May;39(5):573-80 [16648893.001]
  • [Cites] Int J Hematol. 2006 Nov;84(4):337-42 [17118760.001]
  • [Cites] Pathol Res Pract. 2007;203(1):1-7 [17157997.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):643-7 [15357742.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):619-23 [15468433.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63 [8315579.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1488-91 [9780272.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Int J Infect Dis. 2005 Sep;9(5):239-50 [16095940.001]
  • (PMID = 17762574.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / CA109232-04; United States / FIC NIH HHS / TW / 5D43 TW00017-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS191349; NLM/ PMC2855639
  •  go-up   go-down


8. Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O: Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica; 2009 Nov;94(11):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
  • There are data to support a role for genetic and immune-related factors in the pathogenesis of lymphomas and plasma cell diseases.
  • We discuss the overlap in risk factors between related malignancies and explore the underlying mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):717-23 [18021086.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1468-73 [18053453.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):307-11 [8426374.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):361-8 [8347786.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1363-9 [8371587.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2378-85 [8162584.001]
  • [Cites] Scand J Immunol. 1994 Aug;40(2):195-200 [8047841.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1943-9 [8656264.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):1095-7 [8782146.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1753-7 [8983286.001]
  • [Cites] Haematologica. 2005 Jan;90(1):66-71 [15642671.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Blood. 2005 Jul 15;106(2):668-72 [15811955.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Blood. 2006 Feb 1;107(3):904-6 [16210333.001]
  • [Cites] N Engl J Med. 2008 Jul 10;359(2):152-7 [18614782.001]
  • [Cites] Lupus. 2008 Jul;17(7):613-4 [18625632.001]
  • [Cites] Arch Intern Med. 2008 Sep 22;168(17):1903-9 [18809818.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3052-6 [18703425.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735 [18923179.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):29-32 [3970037.001]
  • [Cites] Br J Haematol. 1985 Jul;60(3):551-4 [3925983.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):371-8 [3461199.001]
  • [Cites] Br J Cancer. 1987 Jan;55(1):85-90 [3814482.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2978-81 [3567914.001]
  • [Cites] Leuk Res. 1988;12(1):81-8 [3357350.001]
  • [Cites] Am J Pathol. 1988 Oct;133(1):173-92 [2845789.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):353-7 [3222144.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):63-7 [1536915.001]
  • [Cites] Haematologica. 2009 May;94(5):647-53 [19286886.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):398-405 [19365835.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):91-4 [19438470.001]
  • [Cites] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • [Cites] Blood. 2009 Jul 23;114(4):791-5 [19182202.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1179-81 [19546435.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2147-50 [19582882.001]
  • [Cites] Hum Genet. 2000 May;106(5):553-6 [10914686.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):793-5 [11526388.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1979-81 [11535538.001]
  • [Cites] APMIS. 2001 Nov;109(11):797-800 [11900061.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3909-15 [12010788.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):347-54 [15251127.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Blood. 1966 Apr;27(4):435-48 [5327005.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Scand J Haematol. 1977 Oct;19(4):396-404 [562530.001]
  • [Cites] Cancer. 1977 Nov;40(5):2094-101 [336182.001]
  • [Cites] Acta Med Scand. 1982 May;211(3):237-9 [6805257.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):488-94 [16357024.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] Blood. 2006 Jul 1;108(1):292-6 [16527887.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Semin Immunol. 2006 Oct;18(5):305-17 [16916610.001]
  • [Cites] Am J Hum Genet. 2006 Oct;79(4):695-701 [16960805.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1697-700 [17145609.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3774-81 [17133544.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Cell. 2007 Jul 13;130(1):25-35 [17632054.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1260-7 [17426058.001]
  • [Cites] Expert Opin Pharmacother. 2007 Sep;8(13):2089-107 [17714062.001]
  • (PMID = 19586941.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2770969
  •  go-up   go-down


9. Imamura A: [An updated overview of HAART in HIV-infected adults]. Nihon Rinsho; 2010 Mar;68(3):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, non-AIDS-defining conditions, including liver-related events, cardiovascular disease, chronic kidney disease, and non-AIDS-defining malignancies have gained importance as a cause of morbidity and mortality in the era of HAART.
  • Antiretroviral therapy may be considered in some patients with a CD4 cell count greater than 350 cells/microL for reduction in risk of non-AIDS events.


10. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • Recent descriptions of long-term remissions in patients with posttransplantation EBV-associated PCNSL who received EBV-specific therapy suggest some antitumor effect is anti-EBV mediated.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


11. Yasuoka A: [Opportunistic infections in HIV/AIDS]. Nihon Rinsho; 2010 Mar;68(3):486-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Opportunistic infections in HIV/AIDS].
  • The number of diagnosed AIDS and HIV infection is still increasing year by year in Japan.
  • Increment of malignancies such as malignant lymphoma and Kaposi's sarcoma is remarkable in recent years.
  • Although diagnosis and treatment of OIs are almost established, some novel diagnostic tests and treatment option have developed and imploved the clinical outcome of HIV-related OIs.
  • [MeSH-major] AIDS-Related Opportunistic Infections


12. Dubina M, Goldenberg G: Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol; 2009 Aug;31(6):561-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral-associated nonmelanoma skin cancers: a review.
  • Nonmelanoma skin cancers are the most common malignancies in the United States, with over 1.3 million patients diagnosed yearly.
  • Several types of nonmelanoma skin cancer and precancerous lesions have an associated viral pathogenesis, including epidermodysplasia verruciformis, verrucous carcinoma, bowenoid papulosis, Kaposi sarcoma, squamous cell carcinoma, and, most recently, Merkel cell carcinoma.
  • It is now widely accepted that high-risk human papillomaviruses (HPVs) play a key role in pathogenesis of cervical and anogenital cancer.
  • They can be divided into genera including alpha, beta, and gamma HPVs, which comprise the majority of cutaneous HPvs. The relationship between viruses and cancer is a popular focus of research in an era of AIDS and organ transplantation, where immunosuppression is not uncommon.
  • The incidence of viral-related malignancies in these populations is increasing.
  • Because of the widespread nature of these cutaneous malignancies, an evaluation of these conditions is valuable.
  • This review of the literature will focus on the histologic aspects of viral-associated skin malignancies, as well as the epidemiology, etiology, and clinical aspects of these diseases.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2010 Jul;32(5):522 [20571349.001]
  • (PMID = 19590418.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 195
  •  go-up   go-down


13. Wang J, Stebbing J, Bower M: HIV-associated Kaposi sarcoma and gender. Gend Med; 2007 Sep;4(3):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Kaposi sarcoma and gender.
  • BACKGROUND: Cancer in individuals living with HIV and AIDS is a common source of morbidity and mortality, especially in the underdeveloped world.
  • As antiretrovirals are distributed with greater equity across the globe, individuals with HIV and AIDS are living longer and developing malignancies, as opposed to other opportunistic infections.
  • OBJECTIVE: This article reviews the gender differences in studies of AIDS-associated cancers, examining factors related to transmission, treatment, and outcome.
  • METHODS: MEDLINE, PubMed, Ovid, conference proceedings, and abstract books were searched from 1983 onward for English-language publications and data on gender differences related to AIDS-associated cancers.
  • The search terms used were women or gender, cancer or tumor or malignancy, lymphoma or Kaposi, and HIV or AIDS.
  • CONCLUSION: Immunosuppression-induced malignancies in women, Kaposi sarcoma in particular, are likely to represent a global issue in the future.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / epidemiology


1
Advertisement
4. Ferreira MS, Borges AS: [Histoplasmosis]. Rev Soc Bras Med Trop; 2009 Mar-Apr;42(2):192-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical features may vary from asymptomatic infections to disseminated severe forms that affect patients with acquired immunodeficiency syndrome or hematological malignancies and allograft recipients.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / etiology. Acute Disease. Chronic Disease. Histoplasma / pathogenicity. Humans. Lung Diseases, Fungal / diagnosis. Lung Diseases, Fungal / drug therapy. Lung Diseases, Fungal / microbiology

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448941.001).
  • [ISSN] 1678-9849
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 18
  •  go-up   go-down


15. Kanmogne GD: Noninfectious pulmonary complications of HIV/AIDS. Curr Opin Pulm Med; 2005 May;11(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninfectious pulmonary complications of HIV/AIDS.
  • PURPOSE OF REVIEW: This article reviews recent findings on noninfectious pulmonary complications of HIV/AIDS, with a focus on HIV/AIDS-related lung malignancies and pulmonary hypertension, and discusses their incidence in the highly active antiretroviral therapy (HAART) era.
  • RECENT FINDINGS: Noninfectious pulmonary complications of HIV/AIDS are now recognized as important contributors to morbidity and mortality in HIV-infected patients.
  • This is especially the case for HIV-related lung cancer and other non-AIDS-defining malignancies, which are now being diagnosed with increased frequency in HIV-infected patients.
  • The incidence of Kaposi sarcoma and AIDS-related lymphoma has decreased in the HAART era, but compared with the general population, the risk of these malignancies and pulmonary hypertension is still very high in HIV-infected patients.
  • Concurrent use of HAART and chemotherapy improves prognosis and survival of patients with AIDS-related lymphoma.
  • For patients with HIV-related pulmonary hypertension, some studies show no beneficial effect of HAART whereas other reports show that HAART improves patient survival and response to antihypertensive treatment.
  • SUMMARY: The beneficial effect of HAART and improved immune response on the treatment of Kaposi sarcoma and AIDS-related lymphoma suggests that HIV or viral-induced immunosuppression plays an important role in the development of these malignancies.
  • Evidence from current studies suggests that HAART does not protect against HIV-related lung cancer.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Hypertension, Pulmonary / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology


16. Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A, EuroSIDA Study Group: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer; 2010 Nov 15;116(22):5306-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.
  • BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies.
  • However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.
  • Malignancies were classified as virus-related, non-virus-related epithelial, and other.
  • The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count.
  • Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.
  • RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other.
  • Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group.
  • After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73).
  • Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).
  • CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies.
  • Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20661911.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Losso M; Elias C; Vetter N; Zangerle R; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Delforge M; Colebunders R; Vanderkerckhove L; Hadziosmanovic V; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Kronborg G; Benfield T; Larsen M; Gerstoft J; Katzenstein T; Hansen A-; Skinhoj P; Pedersen C; Larsen OD; Oestergaard L; Zilmer K; Smidt J; Ristola M; Katlama C; Viard J-; Girard P-; Livrozet JM; Vanhems P; Pradier C; Dabis F; Neau D; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Staszewski S; Bogner J; Fatkenheuer G; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambatakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Mayyan S; Vella S; Esposito R; Mazeau I; Mussini C; Arici C; Pristera R; Mazzotta F; Gabbuti A; Vullo V; Lichtner M; Chirianni A; Montesarchio E; Gargiulo M; Antonucci G; Iacomi F; Narciso P; Vlassi C; Zacarelli M; Lazzarin A; Finazzi R; Galli M; Ridolfo A; d'Arminio Monforte A; Rozental B; Zeltina I; Chaplinskas S; Hemmer R; Staub T; Reiss P; Ormaasen V; Maeland A; Bruun J; Knysz B; Gasiorowski J; Horban A; Bakowska E; Grzeszczuk A; Flisiak R; Boron-Kaczmarska A; Pynka M; Parczewski M; Beniowski M; Mularska E; Trocha H; Jablonowska E; Malolepsza E; Wojcik K; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokras M; Stanekova D; Tomazic J; Gonzalez-Lahoz J; Soriano V; Labarga P; Medrano J; Moreno S; Clotet B; Jou A; Paredes R; Tural C; Puig J; Bravo I; Gatell JM; Miro JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Flamholc L; Ledergerber B; Weber R; Francioli P; Cavassini M; Hirschel B; Boffi E; Furrer H; Battegay M; Elzi L; Kravchenko E; Chentsova N; Kutsyna G; Servitskiy S; Antoniak S; Krasnov M; Barton S; Johnson AM; Mercey D; Phillips A; Johnson MA; Mocroft A; Murphy M; Weber J; Scullard G; Fisher M; Leen C
  •  go-up   go-down


17. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME: The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun; 2008 Feb-Mar;30(1-2):90-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progressive multifocal leukoencephalopathy (PML) is a rare and devastating neurological disease with areas of demyelination in the central nervous system classically associated with profound imunosuppression.
  • Once seen primarily in severely immunosuppressed states including lymphoma, solid organ malignancies, and organ transplant recipients, PML became an AIDS-defining illness in the 1980s.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / virology. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Humans. JC Virus / immunology. Magnetic Resonance Imaging. Natalizumab. Rituximab

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191544.001).
  • [ISSN] 0896-8411
  • [Journal-full-title] Journal of autoimmunity
  • [ISO-abbreviation] J. Autoimmun.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Natalizumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 105
  •  go-up   go-down


18. Chang PC, Fitzgerald LD, Van Geelen A, Izumiya Y, Ellison TJ, Wang DH, Ann DK, Luciw PA, Kung HJ: Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res; 2009 Jul 15;69(14):5681-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) has been linked to the development of Kaposi's sarcoma, a major AIDS-associated malignancy, and to hematologic malignancies, including primary effusion lymphoma and multicentric Castleman's disease.
  • Understanding the molecular details associated with this transition from latency to lytic replication is key to controlling virus spread and can affect the development of intervention strategies.
  • Here, we report that Kruppel-associated box domain-associated protein-1 (KAP-1)/transcriptional intermediary factor 1beta, a cellular transcriptional repressor that controls chromosomal remodeling, participates in the process of switching viral latency to lytic replication.
  • In cells harboring latent KSHV, KAP-1 was associated with the majority of viral lytic-gene promoters.

  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40463-70 [11013263.001]
  • [Cites] Virology. 2009 Apr 25;387(1):76-88 [19269659.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):1112-20 [11867539.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):919-32 [11959841.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1785-92 [14742721.001]
  • [Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):2067-78 [8769649.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):83-90 [9934688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4366-78 [10330177.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] J Virol. 2005 Jan;79(1):245-56 [15596820.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):929-37 [15882967.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] EMBO J. 2005 Sep 21;24(18):3279-90 [16107876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16055-9 [16247011.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] J Gen Virol. 2006 Jul;87(Pt 7):1763-79 [16760381.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] Nat Cell Biol. 2006 Aug;8(8):870-6 [16862143.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11594-9 [17178852.001]
  • [Cites] J Biol Chem. 2007 Jan 19;282(3):1595-606 [17079232.001]
  • [Cites] J Virol. 2007 Feb;81(3):1072-82 [17108053.001]
  • [Cites] J Virol. 2007 Mar;81(5):2524-30 [17151105.001]
  • [Cites] J Virol. 2007 May;81(10):5407-12 [17360761.001]
  • [Cites] Mol Cancer. 2007;6:28 [17433107.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e89 [17542650.001]
  • [Cites] Cell. 2007 Oct 5;131(1):46-57 [17923087.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9954-62 [17942928.001]
  • [Cites] Cell Host Microbe. 2007 Jun 14;1(4):275-86 [18005708.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36177-89 [17942393.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):823-37 [18082607.001]
  • [Cites] Nat Rev Microbiol. 2008 Mar;6(3):211-21 [18264117.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3054-9 [18037959.001]
  • [Cites] J Virol. 2008 Jun;82(11):5127-36 [18353941.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jun;15(6):626-33 [18488044.001]
  • [Cites] Mol Biol Cell. 2009 Jan;20(1):296-305 [18923144.001]
  • [Cites] Genes Dev. 2001 Feb 15;15(4):428-43 [11230151.001]
  • (PMID = 19584288.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / P01 DE019085; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / T32 CA108459-03; None / None / / R01 CA111185-01; United States / NCI NIH HHS / CA / CA114575-S1; None / None / / P30 CA093373-010001; United States / NCI NIH HHS / CA / CA108459-02; None / None / / R01 CA111185-04; United States / NCI NIH HHS / CA / CA111185; None / None / / P01 DE019085-010002; United States / NCI NIH HHS / CA / R01 CA111185-04; United States / NCI NIH HHS / CA / CA108459-01A2; United States / NCI NIH HHS / CA / CA108459-03; United States / NCI NIH HHS / CA / T32 CA108459-01A2; United States / NIDCR NIH HHS / DE / DE019085; United States / NCI NIH HHS / CA / R01 CA114575; None / None / / R01 CA111185-02; United States / NCI NIH HHS / CA / R01 CA111185-03; United States / NCI NIH HHS / CA / R01 CA111185-02; None / None / / R01 CA111185-03; United States / NCI NIH HHS / CA / T32 CA108459-02; United States / NCI NIH HHS / CA / R01 CA111185-05; United States / NCI NIH HHS / CA / R01 CA111185; United States / NIDCR NIH HHS / DE / P01 DE019085-020002; United States / NIDCR NIH HHS / DE / P01 DE019085-010002; United States / NCI NIH HHS / CA / R01 CA111185-01; United States / NCI NIH HHS / CA / T32 CA108459; United States / NIDCR NIH HHS / DE / DE019085-020002; United States / NCI NIH HHS / CA / CA111185-05; United States / NCI NIH HHS / CA / P30 CA093373-010001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / Repressor Proteins; 0 / Rta protein, Human herpesvirus 8; 0 / Small Ubiquitin-Related Modifier Proteins; 0 / TRIM28 protein, human; 0 / Trans-Activators; 0 / Viral Proteins; 147336-22-9 / Green Fluorescent Proteins; 452VLY9402 / Serine; EC 2.7.- / Protein Kinases
  • [Other-IDs] NLM/ NIHMS119615; NLM/ PMC2731626
  •  go-up   go-down


19. Blanes M, Belinchón I, Merino E, Portilla J, Sánchez-Payá J, Betlloch I: [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection]. Actas Dermosifiliogr; 2010 Oct;101(8):702-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection].
  • The frequency of opportunistic infections and AIDS-related cancers has fallen, though new health problems have developed.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965013.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


20. Laurido M, Urueña A, Vizzotti C, Bugarin G, Cassetti I: [Incidence variation in malignancies associated or not with AIDS at an outpatient care center, 1997-2005]. Medicina (B Aires); 2007;67(3):243-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence variation in malignancies associated or not with AIDS at an outpatient care center, 1997-2005].
  • In Argentina there are no published data on the incidence of AIDS (ARM) and non-AIDS related malignancies (non-ARM) in the HIV positive population.
  • Our aim was to establish the incidence of these malignancies at an ambulatory care center between 1997 and 2005.
  • We describe 103 cases of malignancies, 73 out of them were ARM and 30 were non-ARM.
  • Among those patients with ARM, simultaneous diagnosis of malignancy and HIV infection was more frequently seen (p <0.001) and the proportion of patients with AIDS was higher (p = 0.015).
  • Among those patients with non-ARM the mean duration of HIV infection and HAART was higher (p = 0.038 and 0.002 respectively); also was higher the mean CD4 count nadir (p = 0.009), and CD4 count at the time of malignancy diagnosis (p <0.001).
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / mortality. Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / mortality. Adult. Antiretroviral Therapy, Highly Active. Argentina / epidemiology. Female. Humans. Immunocompromised Host. Incidence. Male. Retrospective Studies


21. Stebbing J, Duru O, Bower M: Non-AIDS-defining cancers. Curr Opin Infect Dis; 2009 Feb;22(1):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers.
  • PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs).
  • Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear.
  • RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532075.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


22. Kreuter A, Wieland U, Gambichler T, Altmeyer P, Pfister H, Tenner-Racz K, Racz P, Potthoff A, Brockmeyer NH, German Network of Competence HIV/AIDS: p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Br J Dermatol; 2007 Sep;157(3):523-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected patients despite the initiation of highly active antiretroviral therapy.
  • CONCLUSIONS: The significant decrease in p16(ink4a) expression in correlation with the drop of lesional high-risk HPV load suggests that p16(ink4a) may be a useful adjunct for the evaluation of treatment response in HPV-associated malignancies and their precursor lesions.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Administration, Cutaneous. Adult. Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Homosexuality, Male. Humans. Ki-67 Antigen / metabolism. Male. Papillomaviridae / genetics. Papillomavirus Infections / complications. Papillomavirus Infections / metabolism. Pilot Projects. Viral Load

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573882.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Ki-67 Antigen; 99011-02-6 / imiquimod
  •  go-up   go-down


23. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • The observed number of site-specific cancer cases was divided by the expected number to obtain proportional incidence ratio (PIR).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.


24. Rewari BB, Purohit V, Chhabra RM, Bhagwan J: Emergencies in HIV--part 2. J Assoc Physicians India; 2008 Oct;56:783-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a short span of two and a half decades, HIV/AIDS has emerged as second largest killer disease that has affected mankind.
  • Human immunodeficiency virus (HIV) infection is associated with several opportunistic infections/malignancies that may be life threatening and need quick intervention by health care workers.
  • These emergencies could be related to opportunistic infections that are seen at presentation or that occur as the immune system gets weaker, or may bedue to HIV itself per se.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Anti-HIV Agents / adverse effects. Anti-HIV Agents / therapeutic use. Emergency Medical Services. HIV Infections / drug therapy. Immune Reconstitution Inflammatory Syndrome / drug therapy


25. Kiertiburanakul S, Likhitpongwit S, Ratanasiri S, Sungkanuparph S: Malignancies in HIV-infected Thai patients. HIV Med; 2007 Jul;8(5):322-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies in HIV-infected Thai patients.
  • Of 1416 HIV-infected patients seen at Ramathibodi Hospital over a 5-year period (1999-2003), 42 were diagnosed with malignancies, giving a prevalence of 3%.
  • AIDS-related malignancies were found in 26 patients (62%).
  • The most common AIDS-related malignancies were non-Hodgkin's lymphoma (NHL) (33%), cervical cancer (21%) and Kaposi's sarcoma (KS) (5%).
  • Breast cancer was the most common non-AIDS-related malignancy (10%).
  • The 75% survival time of patients who received treatment for their malignancy was longer than that of patients who received no treatment (18.3 vs 1.2 months; P<0.01).


26. Rewari BB, Tanwar S: Emergencies in HIV medicine. J Indian Med Assoc; 2009 May;107(5):317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Opportunistic infections/malignancies make immune system weaker and as these are associated with HIV infection, so need quick intervention.
  • Emergencies related to antiretroviral therapy are: Lactic acidosis, hepatic necrosis, bone marrow suppression and rashes by non-nucleoside reverse transcriptase inhibitor enzyme.
  • [MeSH-major] AIDS-Related Opportunistic Infections / therapy. Anti-HIV Agents / adverse effects. Emergencies. HIV Infections / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886387.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Number-of-references] 12
  •  go-up   go-down


27. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, HIV/AIDS Cancer Match Study: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS; 2006 Aug 1;20(12):1645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in cancer risk among people with AIDS in the United States 1980-2002.
  • BACKGROUND: People with AIDS have heightened cancer risk from immunosuppression.
  • HAART has been available since 1996 and has reduced AIDS-related mortality, but there are few large-scale studies on cancer trends.
  • METHODS: AIDS and cancer registries in 11 US regions (1980-2002) were used to identify cancers in 375 933 people with AIDS.
  • Cancer risk relative to the general population was measured using the standardized incidence ratio (SIR), focusing on the 2 years after AIDS onset for those with AIDS in 1990-1995 and 1996-2002 (HAART era).
  • RESULTS: Between 1990-1995 and 1996-2002, risk declined for the two major AIDS-defining cancers: Kaposi sarcoma [(KS) n = 5131; SIR, 22 100 and 3640, respectively; P < 0.0001] and non-Hodgkin lymphoma [(NHL) n = 3412; SIR, 53.2 and 22.6, respectively; P < 0.0001].
  • Risk of cervical cancer did not change (n = 64; SIR, 4.2 and 5.3, respectively; P = 0.33).
  • Among non-AIDS malignancies, lung cancer was most common, but risk declined between 1990-1995 and 1996-2002 (n = 344; SIR, 3.3 and 2.6, respectively; P = 0.02).
  • CONCLUSIONS: Dramatic declines in KS and NHL were temporally related to improving therapies, especially introduction of HAART, but those with AIDS remain at marked risk.
  • Among non-AIDS-related cancers, a recent increase in Hodgkin lymphoma was observed.


28. Kamana NK, Wanchu A, Sachdeva RK, Kalra N, Rajawanshi A: Tuberculosis is the leading cause of lymphadenopathy in HIV-infected persons in India: results of a fine-needle aspiration analysis. Scand J Infect Dis; 2010 Dec;42(11-12):827-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV infection is associated with a number of opportunistic infections and malignancies frequently involving the lymph nodes.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. HIV Infections / complications. Lymphatic Diseases / epidemiology. Lymphatic Diseases / etiology. Tuberculosis, Lymph Node / epidemiology


29. Bateman H, Rehman A, Valeriano-Marcet J: Vasculitis-like Syndromes. Curr Rheumatol Rep; 2009 Dec;11(6):422-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews some vasculitis-like "mimics," particularly emphasizing viral and bacterial infections, drug-related disorders, various malignancies, and other autoimmune disorders, all of which may have a similar clinical presentation.
  • [MeSH-major] Antiphospholipid Syndrome / diagnosis. Cocaine-Related Disorders / diagnosis. Leukoencephalopathies / diagnosis. Vasculitis / diagnosis. Virus Diseases / diagnosis

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Cocaine.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1998 May;41(5):935-8 [9588747.001]
  • [Cites] Semin Arthritis Rheum. 2006 Jun;35(6):388-95 [16765716.001]
  • [Cites] Medicine (Baltimore). 2001 Nov;80(6):391-404 [11704715.001]
  • [Cites] Rheumatology (Oxford). 1999 Jul;38(7):588-90 [10461469.001]
  • [Cites] Cardiovasc Pathol. 1996 Nov-Dec;5(6):305-14 [25851787.001]
  • [Cites] Ann Intern Med. 2007 Jan 2;146(1):34-44 [17200220.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):250-4 [9207375.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1965-7 [12822650.001]
  • [Cites] Arthritis Rheum. 1993 Aug;36(8):1164-74 [8343192.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):275-81 [15731757.001]
  • [Cites] J Rheumatol. 2004 Oct;31(10):1955-8 [15468359.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):628-34 [11245715.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):337-9 [1852208.001]
  • [Cites] Rheumatology (Oxford). 2007 Oct;46(10):1615-6 [17804455.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):600-1 [10583098.001]
  • [Cites] Autoimmun Rev. 2008 Dec;8(2):144-6 [18700172.001]
  • [Cites] Curr Opin Rheumatol. 2008 Jan;20(1):29-34 [18281854.001]
  • [Cites] Arch Pathol Lab Med. 1992 Mar;116(3):238-41 [1536608.001]
  • [Cites] Arthritis Rheum. 2007 Jul;56(7):2116-28 [17599729.001]
  • [Cites] Curr Rheumatol Rep. 2002 Feb;4(1):83-9 [11798987.001]
  • [Cites] Clin Chest Med. 2008 Sep;29(3):475-92, ix [18539239.001]
  • [Cites] Clin Rheumatol. 2007 Jul;26(7):1192-4 [16788735.001]
  • [Cites] Arthritis Rheum. 1992 Jul;35(7):831-4 [1301018.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):405-13 [10693882.001]
  • [Cites] Ann Neurol. 2004 Feb;55(2):250-6 [14755729.001]
  • [Cites] Ann Intern Med. 1994 Jan 1;120(1):12-7 [8250451.001]
  • [Cites] AIDS. 2008 Sep;22 Suppl 3:S27-33 [18845919.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):16-25 [17506787.001]
  • [Cites] Arthritis Rheum. 2009 Feb;60(2):632 [19180488.001]
  • [Cites] Springer Semin Immunopathol. 2001;23(3):217-29 [11591099.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1546-51 [18438818.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2954-65 [15457464.001]
  • [Cites] J Clin Gastroenterol. 2003 May-Jun;36(5):411-3 [12702983.001]
  • [Cites] Eur Respir J. 1996 Jan;9(1):175-7 [8834352.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1189-201 [9214418.001]
  • [Cites] Am J Med Genet. 1998 Feb 17;75(5):469-80 [9489789.001]
  • [Cites] Clin Nephrol. 1995 May;43(5):348-9 [7634555.001]
  • [Cites] Arthritis Rheum. 2002 Dec 15;47(6):662-9 [12522842.001]
  • [Cites] J Rheumatol. 1995 Feb;22(2):351-5 [7738964.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):226-31 [10643719.001]
  • [Cites] Neurology. 2006 Apr 11;66(7):1121-2 [16606935.001]
  • [Cites] Br J Haematol. 2008 Sep;142(5):819-26 [18637802.001]
  • [Cites] Med Phys. 2002 Oct;29(10):2391-403 [12408314.001]
  • [Cites] Curr Opin Rheumatol. 2008 Jan;20(1):55-60 [18281858.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1036-42 [18356474.001]
  • [Cites] Neurol Sci. 2008 Sep;29 Suppl 2:S269-70 [18690515.001]
  • [Cites] N Engl J Med. 2000 Mar 9;342(10):673-80 [10706896.001]
  • [Cites] Curr Opin Rheumatol. 2008 Jan;20(1):35-9 [18281855.001]
  • [Cites] Ann Thorac Surg. 1999 Jan;67(1):236-8 [10086560.001]
  • [Cites] Mayo Clin Proc. 2005 May;80(5):671-3 [15887436.001]
  • (PMID = 19922732.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


30. Savage P: A new approach to immunotherapy: for AIDS and AIDS-related malignancies. J HIV Ther; 2006 Sep;11(3):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new approach to immunotherapy: for AIDS and AIDS-related malignancies.


31. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


32. Bakken T, He M, Cannon ML: The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells. Virology; 2010 Feb 20;397(2):379-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), an AIDS-related endothelial cell malignancy that is the most common cancer in central and southern Africa.
  • Shp2 is vital to many cytokine-induced signaling pathways and is dysregulated in various infections and malignancies.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 20;105(20):7275-80 [18480264.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):R129-32 [10074424.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4044-58 [10361101.001]
  • [Cites] Clin Immunol. 2005 Mar;114(3):266-77 [15721837.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3686-94 [15749907.001]
  • [Cites] Cell Signal. 2005 Nov;17(11):1323-32 [16084691.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3142-9 [16030196.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):71-7 [10619863.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] Cell Res. 2000 Dec;10(4):279-88 [11191350.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1495-505 [11583976.001]
  • [Cites] Blood. 2002 Jan 15;99(2):457-62 [11781225.001]
  • [Cites] J Virol. 2003 Jan;77(1):57-67 [12477810.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):50190-7 [12384497.001]
  • [Cites] J Virol. 2003 Feb;77(4):2631-9 [12552002.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1398-407 [14551136.001]
  • [Cites] J Virol. 2004 Mar;78(5):2460-71 [14963144.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Science. 1991 May 3;252(5006):668-74 [1708916.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2222-8 [1932742.001]
  • [Cites] J Biol Chem. 1992 Jan 25;267(3):1811-7 [1309799.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1607-11 [8096088.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7577-86 [8246974.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1824-34 [8114715.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 14;268(5208):293-7 [7716523.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Immunity. 1996 Jan;4(1):77-85 [8574854.001]
  • [Cites] Cell. 1996 Apr 5;85(1):15 [8620532.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3685-97 [8668185.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] J Virol. 1996 Nov;70(11):8218-23 [8892957.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Virology. 1997 Feb 17;228(2):371-8 [9123844.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):193-204 [9069265.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10606-11 [16809424.001]
  • [Cites] Mol Pharmacol. 2006 Aug;70(2):562-70 [16717135.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2110-20 [17540846.001]
  • [Cites] J Bioinform Comput Biol. 2007 Aug;5(4):875-93 [17787061.001]
  • [Cites] PLoS One. 2008;3(1):e1520 [18231605.001]
  • [Cites] J Vasc Res. 2008;45(2):153-63 [17962719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • (PMID = 20004456.001).
  • [ISSN] 1096-0341
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI053971-06; United States / NIAID NIH HHS / AI / K08 AI053971; United States / NIAID NIH HHS / AI / K08 AI053971-06; United States / NIAID NIH HHS / AI / K08-AI53971
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / G protein-coupled receptor, Human herpesvirus 8; 0 / NF-kappa B; 0 / Receptors, Chemokine; 0 / Transcription Factor AP-1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11
  • [Other-IDs] NLM/ NIHMS164856; NLM/ PMC2822116
  •  go-up   go-down


33. Noy A: Update on HIV lymphoma. Curr Oncol Rep; 2007 Sep;9(5):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In industrialized nations people infected with HIV remain at increased risk for malignancies despite highly active antiretroviral therapy.
  • In these countries, lymphoma is the most common HIV-associated malignancy.
  • Rituximab likely improves complete response rates, and, possibly overall survival, but is likely associated with increased infections in a subset of patients with very low CD4 counts.
  • Biologic insights have been attained in the spectrum of HIV-associated non-Hodgkin's lymphoma, Hodgkin's lymphoma, and virologic coinfections.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1598-602 [17106439.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):399-402 [16640817.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):e21-5 [16421782.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):661-6 [15875183.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1022-7 [15824995.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Mar;21(3):214-20 [15795527.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):1973-9 [16155145.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3325-30 [11013271.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):673-82 [16177644.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3857-9 [11739198.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3412-4 [16597601.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8116-7 [16258111.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):161-3 [15756687.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Eur J Haematol. 2005 Jan;74(1):70-2 [15613110.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3214-8 [17209054.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] HIV Med. 2005 Jan;6(1):21-6 [15670248.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Haematologica. 2005 Jul;90(7):990-2 [15996943.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Clin Infect Dis. 2006 Feb 1;42(3):411-7 [16392091.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):839-43 [12796473.001]
  • [Cites] Virology. 2005 Nov 10;342(1):38-46 [16122775.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • (PMID = 17706167.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 52
  •  go-up   go-down


34. Lou J, Ruggeri T, Tebaldi C: Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior. Math Biosci Eng; 2006 Apr;3(2):313-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior.
  • For HIV-infected individuals, cancer remains a significant burden.
  • Gaining insight into the epidemiology and mechanisms that underlie AIDS- related cancers can provide us with a better understanding of cancer immunity and viral oncogenesis.
  • In this paper, an HIV-1 dynamical model incorporat- ing the AIDS-related cancer cells was studied.
  • The model consists of three components, cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes, and can have six steady states.
  • We discuss the existence, the stability properties and the biological meanings of these steady states, in par- ticular for the positive one: cancer-HIV-healthy cells steady state.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361826.001).
  • [ISSN] 1547-1063
  • [Journal-full-title] Mathematical biosciences and engineering : MBE
  • [ISO-abbreviation] Math Biosci Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Navarro CM, Shibli JA, Ferrari RB, d'Avila S, Sposto MR: Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome. J Periodontol; 2008 Mar;79(3):562-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative malignancies that may be associated with acquired immunodeficiency syndrome (AIDS).
  • This report presents and discusses two unusual cases of gingival primary extranodal non-Hodgkin's lymphoma (PE-NHL) as the first manifestation of AIDS.
  • RESULTS: The clinicopathological evaluation and the serological HIV examination of the patients led us to the final diagnosis of gingival PE-NHL as the first manifestation of AIDS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Gingival Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315441.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Pancharoen C, Nuchprayoon I, Thisyakorn U, Chokephaibulkit K, Veerakul G, Punpanich W, Kanjanapongkul S, Mekmullica J, Wongsawat J, Bowonkiratikachorn P, Hongsiriwon S, Thanarattanakorn P, Kosalaraksa P, Wiangnon S, Saerejittima A, Kochavate S: Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand. Pediatr Infect Dis J; 2005 Oct;24(10):923-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand.
  • To determine the incidence and spectrum of malignancies in human immunodeficiency virus-infected children, we surveyed 48 hospitals in Thailand between 1996 and 2000.
  • There were 23 children (14 boys and 9 girls; average age at diagnosis of malignancy, 4.2 years), and the incidence rate was 0.6 per 1000 person-years.
  • The most common malignancy was lymphoma (87.0%).
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. HIV Infections / complications. HIV Infections / epidemiology. Hospitals. Lymphoma, AIDS-Related / epidemiology. Neoplasms / epidemiology


37. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den Broeke A: Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol; 2006 Feb;80(4):1922-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection of cattle and sheep with bovine leukemia virus (BLV), a complex retrovirus related to human T-cell leukemia virus type 1 (HTLV-1), is associated with the development of B-cell leukemia.
  • Whereas the natural disease in cattle is characterized by a low tumor incidence, experimental infection of sheep leads to overt leukemia in the majority of infected animals, providing a model for studying the pathogenesis associated with BLV and HTLV-1.
  • Tax(BLV), the major oncoprotein, initiates a cascade of events leading toward malignancy, although the basis of transformation is not fully understood.
  • Using cDNA-spotted microarrays comprising 10,336 human genes/expressed sequence tags, we identified a cohort of differentially expressed genes, including genes related to apoptosis, DNA transcription, and repair; proto-oncogenes; cell cycle regulators; transcription factors; small Rho GTPases/GTPase-binding proteins; and previously reported Tax(HTLV-1)-responsive genes.
  • Interestingly, genes known to be associated with human neoplasia, especially B-cell malignancies, were extensively represented.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13395-401 [11278855.001]
  • [Cites] EMBO J. 2001 May 1;20(9):2273-85 [11331592.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3902-9 [11389033.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):29-38 [11759826.001]
  • [Cites] Dis Markers. 2001;17(3):129-37 [11790876.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):589-95 [11839681.001]
  • [Cites] Blood. 2002 May 1;99(9):3367-75 [11964305.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14877-83 [11836256.001]
  • [Cites] Vet Immunol Immunopathol. 2002 Jul;86(3-4):229-44 [12007889.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):210-5 [12021785.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2309-10 [12057933.001]
  • [Cites] Lab Invest. 2002 Jul;82(7):893-901 [12118091.001]
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):219-23 [12169396.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1795-801 [12176902.001]
  • [Cites] Biotechniques. 2002 Sep;33(3):516-8, 520, 522 passim [12238761.001]
  • [Cites] J Virol. 1987 Aug;61(8):2462-71 [3037109.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3385-9 [2828028.001]
  • [Cites] Leukemia. 1988 Feb;2(2):103-7 [2830439.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9263-7 [2848258.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] EMBO J. 1990 May;9(5):1577-81 [2158445.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3720-4 [1827203.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] J Virol. 1993 Jul;67(7):4078-85 [8389918.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] J Virol. 1995 Dec;69(12):7541-7 [7494260.001]
  • [Cites] Biotechniques. 1996 Apr;20(4):584-91 [8800675.001]
  • [Cites] Oncogene. 1997 Sep;15(11):1289-94 [9315096.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):27-32 [9724090.001]
  • [Cites] J Virol. 1999 Feb;73(2):1054-65 [9882306.001]
  • [Cites] Int Immunol. 1999 Jul;11(7):1139-47 [10383947.001]
  • [Cites] Biol Chem. 1999 Jun;380(6):653-60 [10430029.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):757-62 [10717245.001]
  • [Cites] Leuk Lymphoma. 2000 Mar;37(1-2):39-51 [10721768.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2680-8 [12730682.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3837-46 [12748286.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1261-72 [12761041.001]
  • [Cites] Toxicol Sci. 2003 Aug;74(2):470-84 [12773757.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):87-92 [12880965.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4531-42 [12881710.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1443-8 [12738680.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] J Bone Miner Res. 2003 Aug;18(8):1419-29 [12929931.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):152-60 [12935928.001]
  • [Cites] Arch Virol. 2003 Sep;148(9):1787-804 [14505090.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6497-507 [14528274.001]
  • [Cites] J Biochem. 2003 Sep;134(3):327-31 [14561717.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1242-9 [14578863.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5408-12 [12359745.001]
  • [Cites] EMBO J. 2002 Oct 15;21(20):5487-97 [12374749.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1135-47 [12390248.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4622-8 [12453880.001]
  • [Cites] J Pathol. 2003 Jan;199(1):90-7 [12474231.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):44-9 [12490760.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):507-16 [12555064.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):133-42 [12635176.001]
  • [Cites] Cancer Invest. 2003;21(1):105-36 [12643014.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):2168-77 [12682367.001]
  • [Cites] J Biol Chem. 2003 May 2;278(18):15601-7 [12571245.001]
  • [Cites] Oncol Res. 2003;13(6-10):323-31 [12725521.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):e93 [15247326.001]
  • [Cites] Vet Immunol Immunopathol. 2004 Sep;101(1-2):1-17 [15261689.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1127-36 [15100157.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Immunol Methods. 2000 Apr 3;237(1-2):19-28 [10725448.001]
  • [Cites] J Virol. 2000 Jul;74(13):5872-9 [10846067.001]
  • [Cites] Cancer Lett. 2000 Aug 11;156(2):191-8 [10880769.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1553-77 [10887150.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Adv Cancer Res. 2001;80:189-216 [11034544.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1787-95 [11080828.001]
  • [Cites] J Virol. 2001 Feb;75(3):1095-103 [11152482.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5912-22 [15195138.001]
  • [Cites] J Virol. 1987 Jul;61(7):2175-81 [3035218.001]
  • [Cites] Blood. 2004 Jan 1;103(1):229-35 [12946992.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • (PMID = 16439548.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax
  • [Other-IDs] NLM/ PMC1367148
  •  go-up   go-down


39. Angeletti PC, Zhang L, Wood C: The viral etiology of AIDS-associated malignancies. Adv Pharmacol; 2008;56:509-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The viral etiology of AIDS-associated malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1984 Jul;83(1 Suppl):26s-28s [6330218.001]
  • [Cites] Nature. 1984 Sep 20-26;311(5983):276-9 [6090931.001]
  • [Cites] Virology. 1984 Oct 30;138(2):347-52 [6093371.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):111-4 [2983228.001]
  • [Cites] Am J Pathol. 1985 Jun;119(3):361-6 [2990217.001]
  • [Cites] Science. 1985 Nov 15;230(4727):770-6 [2997917.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):893-7 [10555764.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):581-7 [10591087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21 [10613347.001]
  • [Cites] Acta Histochem Suppl. 1989;37:103-8 [2549568.001]
  • [Cites] J Virol. 1989 Oct;63(10):4417-21 [2476573.001]
  • [Cites] Genitourin Med. 1989 Aug;65(4):276-80 [2807289.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Nature. 1990 Apr 19;344(6268):777-80 [2158628.001]
  • [Cites] Nature. 1990 May 31;345(6274):447-9 [1692971.001]
  • [Cites] J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1237-50 [2193952.001]
  • [Cites] Princess Takamatsu Symp. 1989;20:199-206 [2562182.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):357-70 [1850727.001]
  • [Cites] Transfusion. 2001 Sep;41(9):1120-5 [11552068.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):423-34 [11669604.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Br Med Bull. 2001;58:7-18 [11714621.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] J Virol. 2002 Jan;76(1):455-9 [11739714.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):19-24 [11836442.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1263-71 [11850846.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):155-8 [11857400.001]
  • [Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):418-21 [11917248.001]
  • [Cites] Postgrad Med J. 2002 Apr;78(918):225-8 [11930025.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):926-35 [12072546.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1736-44 [12085319.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] IUBMB Life. 2002 Apr-May;53(4-5):253-8 [12121005.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Sex Transm Dis. 2002 Aug;29(8):427-35 [12172526.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):729-32 [12209615.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):803-9 [12516102.001]
  • [Cites] J Virol. 2003 Apr;77(7):4139-48 [12634372.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] Arch Virol. 2003 May;148(5):871-90 [12721796.001]
  • [Cites] J Infect Dis. 2003 Jun 1;187(11):1780-5 [12751036.001]
  • [Cites] Infection. 2003 Jun;31(3):143-8 [12789471.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] Exp Cell Res. 2000 Jun 15;257(2):332-40 [10837147.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):18871-8 [10770926.001]
  • [Cites] Malays J Pathol. 1998 Jun;20(1):1-10 [10879257.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Lancet. 2000 Sep 23;356(9235):1062-5 [11009141.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Virol. 2001 Mar;75(5):2331-6 [11160736.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2):198-206 [11301383.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Cancer Invest. 2001;19(3):266-72 [11338884.001]
  • [Cites] J Infect Dis. 2001 Jun 1;183(11):1554-64 [11343204.001]
  • [Cites] AIDS. 2001 Jun 15;15(9):1167-74 [11416719.001]
  • [Cites] Am J Hematol. 2001 Jan;66(1):42-5 [11426491.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):248-54 [11463923.001]
  • [Cites] J Infect Dis. 2001 Sep 1;184(5):547-51 [11494160.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Trop Med Hyg. 1995 Aug;98(4):281-4 [7636927.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6218-28 [8557041.001]
  • [Cites] J Virol. 1996 Mar;70(3):1602-11 [8627680.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):714-7 [8627037.001]
  • [Cites] J Mol Biol. 1996 Jun 7;259(2):249-63 [8656427.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1741-8 [8669460.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):470-4 [8651027.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):831-44 [12525917.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2002 Nov-Dec;44(6):309-13 [12532213.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Reprod Immunol. 2003 Feb;58(1):79-91 [12609527.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Virol. 1996 Nov;70(11):8218-23 [8892957.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):364-8 [8900368.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7098-108 [8943365.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1996;117(2):105-10 [8959929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] J Virol. 1997 Jan;71(1):586-94 [8985387.001]
  • [Cites] South Med J. 1977 Aug;70(8):1011-3 [887963.001]
  • [Cites] Clin Exp Dermatol. 1978 Jun;3(2):135-46 [699366.001]
  • [Cites] Cancer. 1978 Dec;42(6):2626-30 [728865.001]
  • [Cites] Transplantation. 1979 Jan;27(1):8-11 [442191.001]
  • [Cites] Am J Med. 1979 Nov;67(5):759-65 [159624.001]
  • [Cites] Int J Cancer. 1980 Jul 15;26(1):23-9 [6263803.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1465-7 [6272112.001]
  • [Cites] Gynecol Oncol. 1981 Oct;12(2 Pt 2):S124-8 [6273261.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Sep 24;31(37):507-8, 513-4 [6815471.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 [6304740.001]
  • [Cites] Med Microbiol Immunol. 2003 Aug;192(3):123-8 [12920585.001]
  • [Cites] Transfusion. 2003 Sep;43(9):1260-8 [12919429.001]
  • [Cites] Curr Opin Oncol. 2003 Sep;15(5):372-8 [12960519.001]
  • [Cites] Curr Opin Oncol. 2003 Sep;15(5):382-8 [12960521.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1463-70 [14576481.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] Virology. 2004 Feb 20;319(2):315-23 [14980491.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] J Womens Health (Larchmt). 2004 Mar;13(2):147-53 [15072728.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Med Virol. 2004 Jul;73(3):481-5 [15170646.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):278-85 [15197783.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Jun;16(4):248-54 [15214648.001]
  • [Cites] Virology. 2004 Aug 1;325(2):320-7 [15246271.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46335-42 [15322136.001]
  • [Cites] Bibl Haematol. 1975 Oct;(43):569-71 [183728.001]
  • [Cites] J Infect Dis. 1998 Aug;178(2):304-9 [9697708.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5219-28 [9710606.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3839-44 [9731493.001]
  • [Cites] J Virol. 1998 Oct;72(10):7900-8 [9733827.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] J Mol Biol. 1998 Oct 30;283(3):529-36 [9784363.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1469-72 [9788958.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Virol. 1999 Feb;73(2):1023-35 [9882303.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4765-8 [9891554.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1986 Apr;65(4):177-9 [3012230.001]
  • [Cites] Mol Cell Biol. 1986 Jan;6(1):7-14 [2946931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Feb;84(4):1070-4 [3029760.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Mol Cell Biol. 1987 Oct;7(10):3582-90 [2446117.001]
  • [Cites] Oncogene. 1987;2(1):41-8 [2830582.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] S Afr Med J. 1999 May;89(5):554-7 [10416461.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):615-20 [10428199.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S5-10 [10430211.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S18-22 [10430213.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1316-9 [10479163.001]
  • [Cites] Cancer Surv. 1998;32:201-29 [10489629.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:388-93 [13881052.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):500-17 [10649240.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] Lancet. 1999 Dec;354 Suppl:SIV62 [10691477.001]
  • [Cites] J Clin Virol. 2000 May;16(3):203-13 [10738139.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Adv Cancer Res. 2000;79:175-200 [10818681.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):515-21 [1318265.001]
  • [Cites] Cancer Surv. 1991;10:5-22 [1821323.001]
  • [Cites] Cancer Surv. 1991;10:53-71 [1821324.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1992 Oct 9;41(40):739-43 [1328839.001]
  • [Cites] Pathologica. 1992 Jul-Aug;84(1092):483-8 [1337200.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2102-9 [8386027.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):181-4 [8387461.001]
  • [Cites] Health Rep. 1993;5(1):87-90 [8334243.001]
  • [Cites] J Virol. 1993 Nov;67(11):6424-31 [8411344.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] Obstet Gynecol. 1994 Feb;83(2):205-11 [8290181.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24058-65 [7523366.001]
  • [Cites] J Med Virol. 1994 Jul;43(3):231-7 [7931183.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 1994 Aug;97(8):1381-92 [7931794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12398-402 [7809048.001]
  • [Cites] Intervirology. 1994;37(3-4):150-8 [7843926.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] J Virol. 1995 May;69(5):2989-97 [7707525.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1995 Jan;31(1):77-83 [7729997.001]
  • [Cites] Pathology. 2005 Dec;37(6):409-19 [16373224.001]
  • [Cites] Obstet Gynecol. 2006 Jan;107(1):18-27 [16394035.001]
  • [Cites] J Neurovirol. 2005;11 Suppl 3:38-44 [16540454.001]
  • [Cites] J Virol. 2006 May;80(9):4431-9 [16611903.001]
  • [Cites] AIDS. 2006 May 12;20(8):1201-4 [16691074.001]
  • [Cites] Semin Oncol Nurs. 2006 May;22(2):80-9 [16720230.001]
  • [Cites] J Virol. 2006 Jun;80(12):6165-70 [16731955.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):473-7 [16761254.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] J Virol. 2006 Jul;80(14):7179-85 [16809323.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):98-102 [16143449.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):449-55 [16894292.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E15 [17134117.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):488-93 [8671548.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] AIDS. 1996 Feb;10(2):175-80 [8838705.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11085-90 [8855313.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5704-9 [10318948.001]
  • [Cites] EMBO J. 1999 Jun 1;18(11):3064-73 [10357818.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2916-24 [10378688.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5759-67 [10409763.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):2002-3 [12799649.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):211-4 [12821368.001]
  • [Cites] J Infect Dis. 2003 Jul 1;188(1):128-36 [12825181.001]
  • [Cites] J Virol. 2003 Jul;77(14):8072-86 [12829846.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72 [12852659.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71 [12865452.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):638-42 [12869403.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] Health Policy Plan. 2003 Sep;18(3):299-305 [12917271.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:429-52 [14466781.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] J Virol. 2004 Dec;78(23):12987-95 [15542650.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):93-100 [15543582.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8782-7 [15574792.001]
  • [Cites] Cancer Invest. 2004;22(5):787-98 [15581059.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] DNA Cell Biol. 2005 Jan;24(1):10-20 [15684715.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S59-66 [15753013.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • [Cites] Trends Mol Med. 2005 Jul;11(7):309-12 [15967719.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Int J Mol Med. 2005 Oct;16(4):559-64 [16142387.001]
  • [Cites] Pediatrics. 2005 Oct;116(4):815-25 [16199688.001]
  • [Cites] J Infect Dis. 2005 Nov 1;192(9):1525-9 [16206066.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Sep;262(9):708-12 [16133466.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Obstet Gynecol Clin North Am. 1996 Dec;23(4):895-916 [8989780.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] J Virol. 1997 Jun;71(6):4649-56 [9151858.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Aust N Z J Ophthalmol. 1997 Aug;25(3):211-5 [9296295.001]
  • [Cites] Virology. 1997 Sep 15;236(1):147-54 [9299627.001]
  • [Cites] J Virol. 1997 Oct;71(10):7167-79 [9311789.001]
  • [Cites] J Virol. 1997 Oct;71(10):7600-8 [9311841.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12592-7 [9356494.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1851-8 [9362452.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] Oral Microbiol Immunol. 1997 Oct;12(5):259-65 [9467378.001]
  • [Cites] J Virol. 1998 Mar;72(3):2160-7 [9499072.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Eur J Med Res. 1998 Mar 23;3(3):127-47 [9502754.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6 [9520415.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] AIDS. 1998 May 28;12(8):952-4 [9631151.001]
  • [Cites] Int J STD AIDS. 1998 May;9(5):268-71 [9639204.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):2046-51 [9650960.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):929-40 [2033429.001]
  • [Cites] Int J STD AIDS. 1991 Mar-Apr;2(2):114-5 [1646036.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] AIDS. 1991 Jun;5(6):715-21 [1883543.001]
  • [Cites] Behring Inst Mitt. 1991 Jul;(89):108-21 [1656929.001]
  • [Cites] Nature. 1991 Oct 31;353(6347):866-8 [1834947.001]
  • [Cites] Biophys J. 1991 Dec;60(6):1445-56 [1663794.001]
  • [Cites] J Virol. 1992 Apr;66(4):2057-66 [1312620.001]
  • [Cites] Med Microbiol Immunol. 1992;180(6):321-6 [1312661.001]
  • [Cites] Arch Virol. 1992;123(3-4):425-49 [1562239.001]
  • (PMID = 18086422.001).
  • [ISSN] 1054-3589
  • [Journal-full-title] Advances in pharmacology (San Diego, Calif.)
  • [ISO-abbreviation] Adv. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCRR NIH HHS / RR / RR15635; United States / NCRR NIH HHS / RR / P20 RR015635-076603; United States / NCRR NIH HHS / RR / RR015635-076603; United States / NCI NIH HHS / CA / CA76958; United States / NCRR NIH HHS / RR / P20 RR015635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 330
  • [Other-IDs] NLM/ NIHMS32609; NLM/ PMC2149907
  •  go-up   go-down


40. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT, HOPS Investigators: AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS; 2010 Jun 19;24(10):1549-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study.
  • OBJECTIVES: To assess the incidence and spectrum of AIDS-defining opportunistic illnesses in the highly active antiretroviral therapy (cART) era.
  • METHODS: We calculated incidence rates per 1000 person-years of observation for the first opportunistic infection, first opportunistic malignancy, and first occurrence of each individual opportunistic illness during 1994-2007.
  • During 1994-1997, 1998-2002, and 2003-2007, respectively, rates of opportunistic infections (per 1000 person-years) were 89.0, 25.2 and 13.3 and rates of opportunistic malignancies were 23.4, 5.8 and 3.0 (P for trend <0.001 for both).
  • During 2003-2007, there were no significant changes in annual rates of opportunistic infections or opportunistic malignancies; the leading opportunistic illnesses (rate per 1000 person-years) were esophageal candidiasis (5.2), Pneumocystis pneumonia (3.9), cervical cancer (3.5), Mycobacterium avium complex infection (2.5), and cytomegalovirus disease (1.8); 36% opportunistic illness events occurred at CD4 cell counts at least 200 cells/microl.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / epidemiology. Immunocompromised Host. Neoplasms / epidemiology


41. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • There were 77 (55.4%) patients on HAART when cancer was diagnosed.
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


42. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, HIV Outpatient Study Investigators: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr; 2006 Sep;43(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: AIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined.
  • MEASUREMENTS: Rates of death, opportunistic disease, and other non-AIDS-defining illnesses (NADIs) determined to be primary or secondary causes of death.
  • Deaths that included AIDS-related causes decreased from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 (P=0.008).
  • Proportional increases in deaths involving liver disease, bacteremia/sepsis, gastrointestinal disease, non-AIDS malignancies, and renal disease also occurred (P=or<0.001, 0.017, 0.006, <0.001, and 0.037, respectively.
  • The percentage of deaths due exclusively to NADI rose from 13.1% in 1996 to 42.5% in 2004 (P<0.001 for trend), the most frequent of which were cardiovascular, hepatic, and pulmonary disease, and non-AIDS malignancies in 2004.
  • Patients dying of NADI causes were more HAART experienced and initiated HAART at higher CD4 cell counts than those who died with AIDS (34.5% vs 16.8%, respectively, received HAART for 4 of more years, P<0.0001; 22.4% vs 7.8%, respectively, initiated HAART with CD4 cell counts of more than 350 cells/microL, P<0.001).
  • CONCLUSIONS: Although overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies.
  • Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes.


43. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr; 2005 Jul 1;39(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cancer diagnosis in persons with AIDS.
  • The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies.
  • Similarly, the prognosis of cancer has also improved.
  • To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000.
  • Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis).
  • Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence.
  • The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types.
  • By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer.
  • For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types.
  • In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers.
  • We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS.
  • Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / mortality. Male. New York City / epidemiology. Prognosis. Registries. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / mortality. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980688.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, Whalen C, Lederman M, Remick SC: Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev; 2005;29(2):133-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capacity building for the clinical investigation of AIDS malignancy in East Africa.
  • PURPOSE: To build capacity in the resource-poor setting to support the clinical investigation and treatment of AIDS-related malignancies in a region of the world hardest hit by the AIDS pandemic.
  • METHODS: An initial MEDLINE database search for international collaborative partnerships dedicated to AIDS malignancies in developing countries failed to identify any leads.
  • Building on the formal Uganda-Case Western Reserve University (Case) Research Collaboration dating back to 1987, established NIH-supported centers of research excellence at Case, and expanding activities in Kenya, scientific and training initiatives, research capital amongst our institutions are emerging to sustain a international research enterprise focused on AIDS and other viral-related malignancies.
  • An oral chemotherapy feasibility trial in AIDS lymphoma is near completion; a second lymphoma trial of byrostatin and vincristine is anticipated and a feasibility trial of indinavir for endemic Kaposi's sarcoma is planned.
  • CONCLUSIONS: In the absence of published reports of evolving international partnerships dedicated to AIDS malignancy in resource constrained settings, we feel it important for such progress on similar or related international collaborative pursuits to be published.


45. Tanaka PY, Hadad DJ, Barletti SC, de Souza SA, Calore EE: Bone marrow biopsy in the diagnoses of infectious and non-infectious causes in patients with advanced HIV infection. J Infect; 2007 Apr;54(4):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: The diagnostic utility of bone marrow aspiration, biopsy and culture was retrospectively examined in 82 patients with HIV/AIDS (median CD4 count 51 microL(-1), range 1-430 microL(-1)) with peripheral cytopenias and/or fever attended at a large tertiary care hospital in Brazil during a one-year period.
  • CONCLUSIONS: Bone marrow biopsy has value in diagnosis of opportunistic infections, malignancies or other conditions in one-third of adult patients with advanced AIDS and fever or cytopenias and should be considered in this patient group.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Bone Marrow / pathology. Fever of Unknown Origin / diagnosis. HIV Infections / complications


46. Schlichemeyer R, Chambers C, Gill MJ: The oncology impact of highly active antiretroviral therapy. J Oncol Pharm Pract; 2007 Mar;13(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers.
  • METHODS: We used the Southern Alberta Clinic (SAC) database to define the incidence and prevalence of AIDS-related cancers in a geographically defined HIV population in both the pre- HAART and HAART eras, and subsequently, the Alberta Cancer Board Pharmacy database to determine the chemotherapy associated costs of the cancer treatment.
  • RESULTS: During both eras, 60% of AIDS-related cancer patients received chemotherapy.
  • The absolute number of patients treated in the pre-HAART era was 70, but during the HAART era, due to the decreased incidence of these cancers, only 13 patients received chemotherapy.
  • The number of distinct regimens used for AIDS cancer treatment standardised, and decreased from 29 to six between eras.
  • CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621563.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


48. Peltier AC, Russell JW: Advances in understanding drug-induced neuropathies. Drug Saf; 2006;29(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuropathy can be a dose-limiting adverse effect for many medications used in life-threatening conditions, such as malignancy and HIV-related disease.
  • Thalidomide, an old therapy currently being utilised for new therapeutic indications (e.g. treatment of haematological malignancies), is associated with a painful, axonal sensorimotor neuropathy that does not improve on withdrawal of the drug.
  • Nucleoside reverse transcriptase inhibitors are important components of highly active antiretroviral therapy, but are associated with a sensory neuropathy that is likely to be due to a direct effect of these drugs on mitochondrial DNA replication.

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Muscle Nerve. 1986 Nov-Dec;9(9):837-44 [3023998.001]
  • [Cites] Oncologist. 2003;8(6):508-13 [14657528.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13 [14523789.001]
  • [Cites] Biomed Pharmacother. 2002 Feb;56(1):4-12 [11905508.001]
  • [Cites] Biomed Pharmacother. 2002 Feb;56(1):20-30 [11905506.001]
  • [Cites] Lancet. 2004 Mar 13;363(9412):892-4 [15031036.001]
  • [Cites] Ann Pharmacother. 2003 Feb;37(2):274-8 [12549960.001]
  • [Cites] Clin Infect Dis. 2001 Dec 1;33(11):1914-21 [11692304.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3918-9 [9850043.001]
  • [Cites] Neurology. 2002 May 14;58(9):1333-7 [12011277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Acta Neurol Scand. 2004 Mar;109(3):188-93 [14763956.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1767-74 [12721253.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):337-40 [12552058.001]
  • [Cites] J Neurol Sci. 2003 Apr 15;208(1-2):105-8 [12639733.001]
  • [Cites] Cell Tissue Res. 2000 Feb;299(2):213-24 [10741462.001]
  • [Cites] HIV Med. 2004 Jan;5(1):11-4 [14731163.001]
  • [Cites] Arch Neurol. 1994 Jul;51(7):726-9 [7912506.001]
  • [Cites] Ann Intern Med. 1994 Jun 1;120(11):970 [8172444.001]
  • [Cites] Arch Neurol. 2004 Jun;61(6):889-92 [15210526.001]
  • [Cites] Neurosci Lett. 2001 Jul 27;308(1):1-4 [11445271.001]
  • [Cites] Atherosclerosis. 2006 Jul;187(1):198-204 [16219312.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Jan;54(11):835-8 [10027656.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):612-28 [15294884.001]
  • [Cites] Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46 [15871765.001]
  • [Cites] Leuk Res. 1998 May;22 Suppl 1:S27-33 [9734697.001]
  • [Cites] Neurology. 2004 Jun 22;62(12):2291-3 [15210898.001]
  • [Cites] Am J Med. 2000 Apr 15;108(6):487-95 [10781782.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Mar;11(2):81-4 [15734664.001]
  • [Cites] Am Heart J. 2001 Aug;142(2):E2 [11479481.001]
  • [Cites] Curr Opin Neurol. 2001 Oct;14(5):655-9 [11562579.001]
  • [Cites] Sex Transm Infect. 2001 Jun;77(3):158-73 [11402222.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Nov 1;200(3):237-50 [15504460.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1042-7 [12682470.001]
  • [Cites] Neurology. 2003 Mar 11;60(5):877-8 [12629253.001]
  • [Cites] Neurol Clin. 2000 Aug;18(3):525-40 [10873229.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):927-31 [12610195.001]
  • [Cites] Curr Opin Neurol. 2002 Oct;15(5):633-8 [12352008.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1767-74 [11919233.001]
  • [Cites] Biochem Pharmacol. 1991 Jun 21;42(1):R5-8 [1648918.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1872-5 [12499476.001]
  • [Cites] J Epidemiol Community Health. 2004 Dec;58(12):1047-51 [15547071.001]
  • [Cites] Crit Care Med. 1997 Aug;25(8):1425-30 [9267960.001]
  • [Cites] J Neurosci Res. 2000 Apr 15;60(2):237-44 [10740229.001]
  • [Cites] South Med J. 1998 Jul;91(7):667-8 [9671841.001]
  • [Cites] Muscle Nerve. 2004 Mar;29(3):387-92 [14981738.001]
  • [Cites] Muscle Nerve. 2000 Aug;23(8):1301-2 [10918274.001]
  • [Cites] JAMA. 2003 Apr 2;289(13):1681-90 [12672737.001]
  • [Cites] AIDS. 2003 May 2;17(7):1094-6 [12700465.001]
  • [Cites] AIDS. 2000 Feb 18;14(3):273-8 [10716503.001]
  • [Cites] Brain. 2004 Mar;127(Pt 3):671-9 [14761904.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):599-606 [10901231.001]
  • [Cites] J Invest Dermatol. 2002 Nov;119(5):1020-6 [12445187.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):423-5 [14599877.001]
  • [Cites] Teratology. 1974 Dec;10(3):283-91 [4456671.001]
  • (PMID = 16454532.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS42056; United States / NINDS NIH HHS / NS / T32 NS07222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Immunosuppressive Agents; 0 / Organoplatinum Compounds; 0 / Reverse Transcriptase Inhibitors; 04ZR38536J / oxaliplatin; 4Z8R6ORS6L / Thalidomide; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 61
  •  go-up   go-down


49. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ: Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:69-127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of KSHV in relation to AIDS-associated oncogenesis.
  • KSHV has been established as the causative agent of KS, PEL, and MCD, malignancies occurring more frequently in AIDS patients.
  • KSHV latent infection and lytic reactivation are characterized by distinct gene expression profiles, and both latency and lytic reactivation seem to be required for malignant progression.
  • As a sophisticated oncogenic virus, KSHV has evolved to possess a formidable repertoire of potent mechanisms that enable it to target and manipulate host cell pathways, leading to increased cell proliferation, increased cell survival, dysregulated angiogenesis, evasion of immunity, and malignant progression in the immunocompromised host.
  • The complex interplay between the two viruses dramatically elevates the risk for development of KSHV-induced malignancies, KS, PEL, and MCD.
  • In fact, clinically significant immune deficiency is not necessary for the induction of KSHV-related malignancy.
  • Because of variables such as lack of access to therapy noncompliance with prescribed treatment, failure to respond to treatment and the development of drug-resistant strains of HIV, KSHV-induced malignancies will continue to present as major health concerns.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):201-9 [10343071.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Jul;73(7):5722-30 [10364323.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] J Virol. 1999 Aug;73(8):6953-63 [10400794.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S58-65 [10430220.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] J Gen Virol. 1999 Aug;80 ( Pt 8):2205-9 [10466820.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):827-40 [10499921.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1851-5 [10513642.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5738-46 [10523854.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:330-63 [14481196.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3349-54 [15271792.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] Cancer Invest. 2004;22(5):774-86 [15581058.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] J Virol. 2005 Feb;79(3):1397-408 [15650166.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1310-8 [15471957.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Science. 2005 Feb 4;307(5710):739-41 [15692053.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3686-94 [15749907.001]
  • [Cites] Chest. 2005 Mar;127(3):762-7 [15764755.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] Blood. 2005 May 15;105(10):3987-94 [15665117.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26216-24 [15878864.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):949-55 [9714182.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2095-6 [9723403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]
  • [Cites] FASEB J. 2006 Jan;20(1):9-22 [16394262.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Virol. 2006 Feb;80(3):1385-92 [16415016.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]
  • [Cites] J Virol. 2006 Mar;80(5):2234-42 [16474131.001]
  • [Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]
  • [Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]
  • [Cites] J Virol. 2006 Mar;80(6):3062-70 [16501115.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] J Gen Virol. 2006 Apr;87(Pt 4):795-802 [16528027.001]
  • [Cites] J Virol. 2006 Apr;80(7):3445-58 [16537612.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3051-61 [16540654.001]
  • [Cites] J Virol. 2006 Apr;80(8):4068-78 [16571823.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Trends Microbiol. 2006 Apr;14(4):169-75 [16531046.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Wkly Epidemiol Rec. 2006 Jan 27;81(4):40 [16671237.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1264-73 [16604194.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] J Virol. 2006 Jun;80(11):5371-82 [16699017.001]
  • [Cites] Virology. 2006 May 10;348(2):309-27 [16546233.001]
  • [Cites] Virology. 2006 Jun 20;350(1):192-205 [16616289.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1262-7 [16615115.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31863-7 [10542211.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • [Cites] Hum Immunol. 1999 Oct;60(10):921-7 [10566591.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] J Gen Virol. 1999 Nov;80 ( Pt 11):2889-900 [10580050.001]
  • [Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] AIDS. 1998 Dec 24;12(18):2481-8 [9875587.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] Ann Biol Clin (Paris). 1999 Jan-Feb;57(1):19-28 [9920963.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Crit Rev Oncog. 1998;9(2):107-24 [9973245.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):243-51 [10068212.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Annu Rev Med. 1999;50:425-40 [10073287.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] J Hum Virol. 1999 Jan-Feb;2(1):19-32 [10200596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Leukemia. 1999 Apr;13 Suppl 1:S110-2 [10232382.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Blood. 2000 May 15;95(10):3032-43 [10807766.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1961-71 [10854219.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2179-83 [10854238.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):332-5 [10861641.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):43-7 [10884921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):2049-58 [10900044.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]
  • [Cites] J Virol. 2000 Sep;74(17):8194-201 [10933732.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Virol. 2000 Oct;74(20):9646-54 [11000237.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8254-63 [11027294.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2217-8 [11061672.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):25-36 [11082272.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 1;124(1):16-9 [11165317.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1864-9 [11160685.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2345-52 [11160738.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Mar;75(6):2866-78 [11222712.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):187-98 [11252894.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):156-63 [16014885.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] Trends Immunol. 2005 Sep;26(9):469-76 [16006187.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4840-3 [16145154.001]
  • [Cites] J Virol. 2005 Oct;79(19):12173-84 [16160144.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2790-7 [15976177.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1110-7 [16043440.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Oct;21(10):869-75 [16225414.001]
  • [Cites] J Virol. 2005 Nov;79(21):13618-29 [16227282.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] J Virol. 2005 Nov;79(22):14457-64 [16254382.001]
  • [Cites] Virology. 2005 Dec 5;343(1):47-64 [16154170.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):193-8 [9653095.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] Adv Cancer Res. 2001;81:125-59 [11430594.001]
  • [Cites] Adv Cancer Res. 2001;81:161-200 [11430595.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Aug;75(15):7161-74 [11435597.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Gen Virol. 2001 Aug;82(Pt 8):1965-70 [11458004.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 25;1540(1):1-21 [11476890.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Virol. 2001 Sep;75(18):8660-73 [11507211.001]
  • [Cites] J Virol. 2001 Sep;75(18):8761-71 [11507221.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33805-11 [11448967.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3848-51 [11559722.001]
  • [Cites] J Virol. 2001 Nov;75(22):10933-40 [11602733.001]
  • [Cites] J Virol. 2001 Dec;75(23):11583-93 [11689640.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45979-87 [11590141.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3987-99 [11739795.001]
  • [Cites] J Pathol. 2001 Dec;195(5):586-92 [11745695.001]
  • [Cites] Biotechniques. 2001 Dec;31(6):1286, 1288, 1290, passim [11768657.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Gen Virol. 2002 Jan;83(Pt 1):179-88 [11752715.001]
  • [Cites] J Virol. 2002 Jan;76(2):802-16 [11752170.001]
  • [Cites] Blood. 2002 Jan 15;99(2):649-54 [11781250.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):23-9 [11786394.001]
  • [Cites] J Virol. 2002 Feb;76(4):1744-52 [11799169.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1226-34 [11801659.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d358-75 [11815281.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):791-5 [11857356.001]
  • [Cites] J Leukoc Biol. 2002 Mar;71(3):445-57 [11867682.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2634-43 [11884427.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2000 Jan;74(1):436-46 [10590133.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Virology. 2000 Jan 5;266(1):17-25 [10612656.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1151-7 [10666184.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] J Vasc Res. 2000 Jan-Feb;37(1):1-7 [10720880.001]
  • [Cites] J Virol. 2000 Apr;74(8):3659-67 [10729142.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7 [10733899.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1180-9 [10741750.001]
  • [Cites] J Clin Virol. 2000 May;16(3):203-13 [10738139.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] Mol Med. 1998 Jun;4(6):402-12 [10780883.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):729-36 [10793109.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2002 Sep;76(17):8797-807 [12163600.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1940-9 [10837173.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):209-10 [10843538.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):404-11 [12226829.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):229-41 [12242155.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):975-83 [12352970.001]
  • [Cites] Virology. 2002 Sep 30;301(2):293-304 [12359431.001]
  • [Cites] J Virol. 2002 Nov;76(22):11491-504 [12388711.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2002 Dec;76(23):11880-8 [12414930.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Pathol. 2002 Dec;198(4):511-6 [12434421.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44765-71 [12235164.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Jan;77(1):592-9 [12477863.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] Annu Rev Med. 2003;54:285-303 [12525676.001]
  • [Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):1-3 [12556950.001]
  • [Cites] J Gen Virol. 2003 Feb;84(Pt 2):329-36 [12560564.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Mar;77(6):3878-81 [12610165.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] J Virol. 2003 Apr;77(7):4221-30 [12634379.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Gen Virol. 2003 May;84(Pt 5):1123-31 [12692277.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] J Virol. 2003 Jun;77(11):6188-96 [12743275.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):129-35 [12769790.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1485-91 [12771417.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2001 Apr;75(8):3948-59 [11264383.001]
  • [Cites] J Virol. 2001 Apr;75(8):4008-13 [11264393.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2374-80 [11290600.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):523-30 [11313983.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):800-11 [11314014.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):499-516 [11313008.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):545-67 [11313011.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):245-57 [11325605.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):833-43 [11336706.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jun;125(6):785-9 [11371231.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Dermatol Sci. 2001 Jul;26(3):182-93 [11390203.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):72-84 [14729610.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Herpes. 2003 Dec;10(3):72-7 [14759339.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:237-48 [15033728.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] J Med Primatol. 2004 Feb;33(1):1-9 [15061726.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Blood. 2004 May 1;103(9):3465-73 [14726403.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Gen Virol. 2004 Jun;85(Pt 6):1347-61 [15166416.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27088-97 [15102829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9399-404 [15190178.001]
  • [Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Front Biosci. 1997 Mar 1;2:d126-46 [9159220.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5770-80 [15235582.001]
  • [Cites] Virus Genes. 2004 Oct;29(2):175-82 [15284477.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):387-96 [15288264.001]
  • [Cites] J Virol. 2004 Sep;78(17):9336-42 [15308728.001]
  • [Cites] J Interferon Cytokine Res. 2004 Aug;24(8):439-54 [15320958.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2906-14 [15326101.001]
  • [Cites] J Virol. 2004 Sep;78(18):10187-92 [15331751.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2245-72 [15353285.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Virology. 2004 Oct 10;328(1):7-18 [15380353.001]
  • [Cites] J Med Virol. 2004 Nov;74(3):390-6 [15368522.001]
  • [Cites] J Virol. 2004 Oct;78(20):11108-20 [15452231.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12023-31 [11821384.001]
  • [Cites] J Virol. 2002 May;76(9):4390-400 [11932406.001]
  • [Cites] Biol Chem. 2002 Feb;383(2):255-61 [11934263.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5573-8 [11943871.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] J Virol. 2002 May;76(10):4688-98 [11967286.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] DNA Cell Biol. 2002 Mar;21(3):151-62 [12015894.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Lancet Infect Dis. 2002 May;2(5):281-92 [12062994.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1535-45 [12075072.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Virology. 2002 Jul 5;298(2):181-8 [12127781.001]
  • [Cites] J Cutan Pathol. 2002 Feb;29(2):72-8 [12150136.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):652-9 [12152166.001]
  • [Cites] Science. 1993 Feb 12;259(5097):971-4 [8438157.001]
  • [Cites] Medicine (Baltimore). 1993 Jul;72(4):245-61 [8341141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1291-6 [7692824.001]
  • [Cites] J Virol. 1994 Mar;68(3):1886-902 [8107249.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):191-6 [8062214.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2711-20 [7522639.001]
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1125-31 [7526889.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Res Virol. 1994 May-Aug;145(3-4):251-9 [7528440.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3582-92 [7897237.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1043-4 [7723505.001]
  • [Cites] Lancet. 1995 May 6;345(8958):1180 [7723569.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):596-9 [7637809.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):798; author reply 798-9 [7643891.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Gene Ther. 1994 May;1(3):208-16 [7584083.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] J Emerg Med. 1995 Sep-Oct;13(5):671-4 [8530789.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):450-5 [8618237.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):799-809 [8631301.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):542-9 [8627015.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):816-8 [8752276.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):1120-1 [8783733.001]
  • [Cites] AIDS. 1996 Feb;10(2):175-80 [8838705.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):285-91 [12856221.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Intervirology. 2003;46(3):141-9 [12867751.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9346-58 [12915550.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] J Virol. 2003 Sep;77(18):9758-68 [12941884.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] APMIS. 2003 Jul-Aug;111(7-8):698-714 [12974773.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1113-22 [13679525.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] J Leukoc Biol. 2003 Nov;74(5):757-63 [12960240.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] AIDS. 1996 Sep;10(10):1101-5 [8874626.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52437-45 [14563855.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):514-23 [14724579.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):490-5 [9040590.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Lancet. 1997 Mar 15;349(9054):774-5 [9074581.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1193-7 [9129084.001]
  • [Cites] AIDS. 1997 May;11(6):713-21 [9143602.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):748-50 [9191012.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Lymphology. 1997 Jun;30(2):63-76 [9215976.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1656-9 [9287217.001]
  • [Cites] AIDS. 1997 Sep;11(11):1333-40 [9302442.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2826-9 [9326251.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] J Pathol. 1997 Jul;182(3):262-5 [9349227.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Virol. 1998 Jan;72(1):701-7 [9420276.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3537-42 [9520401.001]
  • [Cites] Nat Med. 1998 Apr;4(4):435-40 [9546789.001]
  • [Cites] J Virol. 1998 Jun;72(6):4980-8 [9573267.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] J Virol. 1998 Jul;72(7):5433-40 [9620998.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Virol. 2004 Nov;78(21):11926-38 [15479833.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2903-11 [15231571.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2736-8 [15238422.001]
  • [Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]
  • [Cites] J Natl Cancer Inst. 1972 Dec;49(6):1509-26 [4647841.001]
  • [Cites] Am J Dermatopathol. 1981 Summer;3(2):111-4 [7270808.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] J Am Acad Dermatol. 1981 Oct;5(4):468-71 [7287964.001]
  • [Cites] N Engl J Med. 1981 Dec 10;305(24):1439-44 [6272110.001]
  • [Cites] Ariz Med. 1981 Dec;38(12):902-4 [7332494.001]
  • [Cites] JAMA. 1986 Jul 4;256(1):20-1, 24-5 [3012133.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Cell. 1989 Aug 25;58(4):729-39 [2475256.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2448-57 [2342456.001]
  • [Cites] Cell. 1991 Sep 20;66(6):1071-4 [1833062.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 [1567395.001]
  • [Cites] Cancer Surv. 1991;10:5-22 [1821323.001]
  • [Cites] J Biol Chem. 1992 Dec 15;267(35):25589-96 [1460054.001]
  • [Cites] Gene Expr. 1992;2(4):329-37 [1472868.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):528-37 [8342600.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • (PMID = 17672038.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA124332-03; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NIDCR NIH HHS / DE / R01 DE017333-03; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NIDCR NIH HHS / DE / DE017333-02; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NIDCR NIH HHS / DE / R01 DE017333-02; United States / NCI NIH HHS / CA / R01 CA096512-05; United States / NCI NIH HHS / CA / R01 CA132637-02; United States / NIDCR NIH HHS / DE / DE017333-01; United States / NCI NIH HHS / CA / CA096512-02; United States / NIDCR NIH HHS / DE / DE017333-03; United States / NIDCR NIH HHS / DE / R01 DE017333; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NIDCR NIH HHS / DE / R01 DE017333-01; United States / NCI NIH HHS / CA / R01 CA132637; United States / NCI NIH HHS / CA / R01 CA132637-01A1; United States / NCI NIH HHS / CA / R01 CA124332-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 504
  • [Other-IDs] NLM/ NIHMS165766; NLM/ PMC2798888
  •  go-up   go-down


50. Ajjampur SS, Sankaran P, Kang G: Cryptosporidium species in HIV-infected individuals in India: an overview. Natl Med J India; 2008 Jul-Aug;21(4):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other susceptible populations studied include patients with malignancies and transplant recipients.
  • With easier access to antiretroviral therapy for Indian patients with HIV, the effect on the prevalence of cryptosporidiosis and aetiology of HIV-related diarrhoea remains to be seen.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Cryptosporidiosis / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cryptosporidiosis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267039.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI042853
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 105
  •  go-up   go-down


51. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I: Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm; 2005 Jan;59(1):177-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taxol is a marketed product for the treatment of ovarian, breast, non-small cell lung cancer and AIDS-related Kaposi's Sarcoma.

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GLYCERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567316.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Liposomes; 0 / Pharmaceutical Vehicles; 0 / Solvents; 6D4M1DAL6O / cremophor EL; P88XT4IS4D / Paclitaxel; PDC6A3C0OX / Glycerol
  •  go-up   go-down


52. Nohle DG, Ayers LW: The tissue microarray data exchange specification: a document type definition to validate and enhance XML data. BMC Med Inform Decis Mak; 2005 May 04;5:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AIDS and Cancer Specimen Resource (ACSR) is a HIV/AIDS tissue bank consortium sponsored by the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD).
  • The ACSR offers HIV-related malignancies and uninfected control tissues in microarrays (TMA) accompanied by de-identified clinical data to approved researchers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • (PMID = 15871741.001).
  • [ISSN] 1472-6947
  • [Journal-full-title] BMC medical informatics and decision making
  • [ISO-abbreviation] BMC Med Inform Decis Mak
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531; United States / NCI NIH HHS / CA / U01 CA66531
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1183103
  •  go-up   go-down


53. Bernstein WB, Little RF, Wilson WH, Yarchoan R: Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol; 2006 Jul;84(1):3-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
  • Since the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic, malignancies have been an important feature of this disease.
  • Several cancers, including Kaposi sarcoma (KS), certain aggressive B-cell lymphomas, and cervical cancer, are considered AIDS-defining when they occur in patients infected with human immunodeficiency virus.
  • Most AIDS-defining tumors are associated with one of 3 DNA viruses: KS-associated herpesvirus, Epstein-Barr virus, or human papillomavirus.
  • With the introduction of highly active antiretroviral therapy (HAART), the incidence of KS and certain lymphomas has decreased, whereas that of other tumors, such as cervical cancer, has undergone little change.
  • Several new drugs and therapies have been developed for KS and AIDS-related lymphomas, and these treatments, plus the development of HAART, have contributed to improvements in morbidity and mortality.
  • At the same time, the improved overall survival of patients with HAART has contributed to an increase in the number of patients living with AIDS in developed countries such as the United States.
  • With the development of HAART and improved prevention and treatment of opportunistic infections, an increasing percentage of the deaths in AIDS patients have been from malignancies.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related. Sarcoma, Kaposi
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. AIDS-Related Opportunistic Infections / mortality. AIDS-Related Opportunistic Infections / prevention & control. AIDS-Related Opportunistic Infections / virology. Humans

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Leuk Lymphoma. 1994 Feb;12(5-6):413-9 [8180604.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1433-43 [9626048.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1799-802 [12218392.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Curr Opin Oncol. 2000 Mar;12(2):174-80 [10750730.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2):143-53 [12704591.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Am J Med. 1991 Apr;90(4):427-33 [1707230.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] AIDS. 2004 Aug 20;18(12):1737-40 [15280789.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Jul 25;17(11):F17-22 [12853764.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Histopathology. 1994 Jul;25(1):77-82 [7959648.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1093-9 [10400426.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):24-5 [9422503.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2876-82 [12885804.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):19-22 [9488122.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1471-6 [15784870.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] N Engl J Med. 1983 May 5;308(18):1071-6 [6835320.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Jun 4;31(21):277-9 [6808345.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Lancet. 1995 Jul 1;346(8966):26-8 [7603142.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2353-64 [8708728.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2173-6 [11264189.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • (PMID = 16867895.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Japan
  • [Number-of-references] 97
  •  go-up   go-down


54. Sunil M, Reid E, Lechowicz MJ: Update on HHV-8-Associated Malignancies. Curr Infect Dis Rep; 2010 Mar;12(2):147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on HHV-8-Associated Malignancies.
  • The human herpesvirus 8 (HHV-8) is the oncogenic virus associated with Kaposi's sarcoma (KS) and lymphoproliferative disorders, namely, primary effusion lymphoma and multicentric Castleman's disease.
  • KS is among the most common malignancies seen in HIV-infected patients despite the decreased incidence of KS in the era of highly active antiretroviral therapy.
  • This review summarizes the recent developments in the fields of virus transmission, molecular biology, and treatment of HHV-8-related neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2008 Feb;82(3):1518-25 [18032494.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]
  • [Cites] Blood. 2008 May 1;111(9):4731-40 [18199825.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):182-8 [18234418.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1236-7 [18525275.001]
  • [Cites] Clin Infect Dis. 2008 Sep 1;47(5):684-8 [18652555.001]
  • [Cites] Transplantation. 2008 Sep 15;86(5):738-44 [18791457.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] J Clin Virol. 2009 Jan;44(1):81-3 [18835212.001]
  • [Cites] J Virol. 1999 May;73(5):4156-70 [10196312.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3279-81 [11050015.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1054-62 [16544245.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Nat Genet. 2006 Jun;38 Suppl:S25-30 [16736021.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1352-60 [16828498.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Pathol Int. 2006 Oct;56(10):617-24 [16984619.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1078-88 [16991082.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1550-8 [17047149.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1129-35 [17154170.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):498-503 [18260115.001]
  • [Cites] Am J Transplant. 2008 Mar;8(3):707-10 [18261181.001]
  • [Cites] Am J Transplant. 2008 Apr;8(4):906-7 [18294348.001]
  • [Cites] J Virol. 2008 May;82(9):4235-49 [18305042.001]
  • [Cites] Virology. 2008 May 25;375(1):94-102 [18321555.001]
  • [Cites] Br J Haematol. 2008 May;141(4):559-61 [18341641.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):601-2 [18410904.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] AIDS. 2008 May 11;22(8):937-45 [18453853.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1006-12 [18469709.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):311-20 [18515794.001]
  • [Cites] AIDS. 2008 May 31;22(9):1019-28 [18520345.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1232-4 [18525273.001]
  • [Cites] Curr Opin Infect Dis. 2007 Apr;20(2):152-6 [17496573.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):199-207 [17570106.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5297-9 [18854561.001]
  • [Cites] Semin Cancer Biol. 2008 Dec;18(6):423-36 [18948197.001]
  • [Cites] Int Urol Nephrol. 2009;41(3):679-85 [19009366.001]
  • [Cites] J Med Virol. 2008 Dec;80(12):2153-60 [19040293.001]
  • [Cites] Transplantation. 2009 Jan 27;87(2):157-63 [19155967.001]
  • [Cites] Mod Pathol. 2009 May;22(5):618-26 [19287457.001]
  • [Cites] J Infect Dis. 2009 Aug 1;200(3):430-8 [19534596.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1867-74 [19554030.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] Br J Haematol. 2009 Nov;147(3):405-8 [19681885.001]
  • [Cites] J Korean Med Sci. 2009 Oct;24(5):970-4 [19795003.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3350-6 [17664482.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2360-70 [17699731.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1439-45 [17721201.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • (PMID = 20461118.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Tornesello ML, Loquercio G, Tagliamonte M, Rossano F, Buonaguro L, Buonaguro FM: Human papillomavirus infection in urine samples from male renal transplant patients. J Med Virol; 2010 Jul;82(7):1179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal allograft recipients have a well-documented increased incidence of human papillomavirus (HPV)-related malignancies and preventive strategies should be specifically implemented.
  • While in females the use of the Papanicolau test and HPV detection assay are used currently as a screening test for cervical cancer, no diagnostic procedures have been implemented to monitor HPV infection in males.
  • The high prevalence of HPV 16 among renal allograft recipients suggests that an HPV-16-based preventive or therapeutic vaccine may be effective for prevention or treatment of HPV-related neoplasia in this group of immune compromised patients.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20513081.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


56. Arav-Boger R: Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes; 2009 Apr;38(2):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease.
  • This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Crit Rev Immunol. 2007;27(5):401-14 [18197804.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):203-9 [9665496.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:289-307 [17089802.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] Int J STD AIDS. 1999 Jun;10 (6):369-75 [10414879.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1721-4 [7903123.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] J Clin Oncol. 1986 Apr;4(4):544-51 [3958767.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34510-24 [17881360.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):642-52 [15765147.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):763-83 [12852655.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1792-801 [17568816.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):495-504 [17371197.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Mar;22(3):297-302 [18269597.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):417-25 [2415251.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1444-9 [9552050.001]
  • [Cites] Cancer Invest. 2005;23 (8):653-9 [16377582.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1712-9 [16520466.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):659-62 [17001705.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1112-21 [9508198.001]
  • [Cites] Nat Med. 2008 Oct;14(10):1118-22 [18776891.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1097-102 [10339664.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):167-76 [17267331.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1000-6 [16570046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7046-50 [1323124.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] Leukemia. 1994;8 Suppl 3:S26-32 [7808021.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] Infection. 2005 Jun;33(3):140-7 [15940415.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):589-99 [17465719.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):823-9 [7850796.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2634-9 [16638877.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] AIDS. 1998 Nov 12;12(16):2169-76 [9833858.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2205-9 [17890905.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1736-42 [9586886.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):81-4 [14758138.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4159-68 [9199351.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Ann Intern Med. 1990 Jun 1;112(11):812-21 [1971504.001]
  • [Cites] J Virol. 2003 Mar;77(5):3301-6 [12584354.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • (PMID = 19139983.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antiviral Agents; 0 / Immunologic Factors
  • [Number-of-references] 71
  •  go-up   go-down


57. Kalantar-Zadeh K, Balakrishnan VS: The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int; 2006 Oct;10(4):315-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The KDW is closely related to oxidative stress (SOX).
  • Such SOX markers as serum myeloperoxidase are associated with pro-inflammatory cytokines and poor survival in MHD patients.
  • Understanding the factors that modulate the KDW/SOX complex and their associations with genetic polymorphism, nutrition, and outcomes in MHD patients may lead to developing more effective strategies to improve outcomes in this and the 20 to 30 million Americans with chronic disease states such as individuals with chronic heart failure, advanced age, malignancies, AIDS, or cachexia.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014506.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK061162-05; United States / NIDDK NIH HHS / DK / R01 DK078106; United States / NIDDK NIH HHS / DK / K23 DK061162; United States / NIDDK NIH HHS / DK / R01 DK078106-01; United States / NIDDK NIH HHS / DK / K23DK61162; United States / NIDDK NIH HHS / DK / K08DK002819; None / None / / K23 DK061162-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cytokines; 0 / Lipoproteins
  • [Number-of-references] 115
  •  go-up   go-down


58. Siemieniuk E, Skrzydlewska E: [Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans]. Postepy Hig Med Dosw (Online); 2005;59:150-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased levels of coenzyme Q10 in humans are observed in many pathologies (e.g. cardiac disorders, neurodegenerative diseases, AIDS, cancer) associated with intensive generation of free radicals and their action on cells and tissues.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928598.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Coenzymes; 0 / Free Radicals; 1339-63-5 / Ubiquinone; EJ27X76M46 / coenzyme Q10
  • [Number-of-references] 57
  •  go-up   go-down


59. Hayun R, Shpungin S, Malovani H, Albeck M, Okun E, Nir U, Sredni B: Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer. Ann N Y Acad Sci; 2007 Jan;1095:240-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tyrosine kinase Fer is essential for the proliferation of numerous malignant cell lines and in some cases was related to Stat3 activation.
  • We show that Fer was associated with Stat3 in PBMC and RAW 264.7, a macrophage cell line.
  • We conclude that anti-IL-10 treatment using AS101, may be beneficial in certain malignancies and other pathologies in which IL-10 secretion is elevated and Stat3 is continuously phosphorylated.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404037.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Ethylenes; 0 / ammonium trichloro(dioxoethylene-O,O'-)tellurate; 110736-90-8 / proto-oncogene protein c-fes-fps; 130068-27-8 / Interleukin-10; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


60. Gichuhi S, Irlam JJ: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev; 2007;(2):CD005643
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region.
  • SEARCH STRATEGY: Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the following electronic databases; Medline/PubMed, CENTRAL, AIDSearch, EMBASE, LILACS, African Healthline, Cochrane HIV/AIDS Specialised Register, and the Cochrane Cancer Network Specialised Register.
  • We searched the clinical trial register of the US National Institutes of Health, searched the international conference proceedings of AIDS and AIDS-related cancers, and contacted individual researchers, research organisations, and pharmaceutical companies that manufacture the drugs used as interventions.
  • HIV/AIDS research has not focused on treatment of this tumour.


61. Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B: The changing face of HIV/AIDS in treated patients. Curr HIV Res; 2009 Jul;7(4):365-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing face of HIV/AIDS in treated patients.
  • Typical AIDS-defining illnesses have been substituted by new comorbid conditions that threaten even those patients who maintain virologic suppression.
  • Proper management of cardiovascular risk, and early diagnosis of AIDS-related and, particularly, non-AIDS-related malignancies (including papilomavirus-related neoplasms) must be introduced into the routine of care.
  • Hot areas of investigation include HIV-associated neurocognitive disorders, hepatitis B and C coinfection, non-alcoholic fatty liver disease, progressive multifocal leukoencephalopathy and tuberculosis.
  • [MeSH-minor] AIDS-Related Complex / epidemiology. AIDS-Related Complex / therapy. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / therapy. Cardiovascular Diseases / epidemiology. Cardiovascular Diseases / therapy. HIV-Associated Lipodystrophy Syndrome / epidemiology. HIV-Associated Lipodystrophy Syndrome / therapy. Humans. Immune Reconstitution Inflammatory Syndrome / therapy. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy. Neoplasms / epidemiology. Neoplasms / therapy


62. Symeonidou C, Standish R, Sahdev A, Katz RD, Morlese J, Malhotra A: Imaging and histopathologic features of HIV-related renal disease. Radiographics; 2008 Sep-Oct;28(5):1339-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and histopathologic features of HIV-related renal disease.
  • Opportunistic infections including those caused by atypical organisms, malignancies such as lymphoma and Kaposi sarcoma, and disease processes specific to HIV infection such as HIV-associated nephropathy have all been shown to affect the kidneys.
  • Furthermore, the introduction of HAART has increased survival of HIV-infected patients; consequently, the frequency of HIV-associated and incidental renal disease is expected to rise in this population.
  • [MeSH-major] AIDS-Associated Nephropathy / diagnosis. AIDS-Associated Nephropathy / etiology. Antiretroviral Therapy, Highly Active / adverse effects. Diagnostic Imaging / methods. HIV Infections / complications. HIV Infections / diagnosis. Kidney / pathology. Kidney / radiography


63. Gangneux JP, Camus C, Philippe B: Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients. Rev Mal Respir; 2010 Oct;27(8):e34-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Invasive aspergillosis is a major cause of mortality in allogeneic bone marrow transplant recipients and patients treated for blood malignancies.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Antibodies, Fungal / blood. Antifungal Agents / therapeutic use. Aspergillus / immunology. Aspergillus / isolation & purification. Aspergillus / physiology. Chronic Disease. Fungemia / diagnosis. Fungemia / drug therapy. Fungemia / epidemiology. Fungemia / physiopathology. Humans. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Lung Diseases / complications. Lung Diseases / immunology. Mannans / blood. Neutropenia. Organ Transplantation. Postoperative Complications / epidemiology. Postoperative Complications / microbiology. Pulmonary Aspergillosis / blood. Pulmonary Aspergillosis / drug therapy. Pulmonary Aspergillosis / epidemiology. Pulmonary Aspergillosis / pathology. Pulmonary Aspergillosis / physiopathology. Pulmonary Aspergillosis / radiography. Respiratory System / microbiology. Risk Factors. Wound Infection / epidemiology. Wound Infection / microbiology

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • HIV InSite. treatment guidelines - Aspergillosis and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20965392.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Fungal; 0 / Antifungal Agents; 0 / Immunosuppressive Agents; 0 / Mannans; 11078-30-1 / galactomannan
  •  go-up   go-down


64. Imam I: The neurology of HIV infection--a review of the literature. Niger J Med; 2005 Apr-Jun;14(2):121-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The manifestation may be a direct effect of the virus, the result of opportunistic infections or secondary malignancies, or a result of the therapy of various aspects of the disease.
  • METHODS: The review was sourced mainly by Medline search using the search terms HIV, AIDS and neurology.
  • RESULTS: The major neurological manifestations of HIV infection are toxoplasmosis, cryptococcal meningitis, AIDS dementia complex, primary lymphoma, tuberculosis, progressive multifocal leukoencephalopathy, herpes zoster, Bells palsy, peripheral neuropathy, and vacuolar myelopathy.
  • [MeSH-major] AIDS-Related Opportunistic Infections / physiopathology. Nervous System Diseases / virology. Neurology. Peripheral Nervous System Diseases / virology


65. Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E: Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther; 2010 Jun;8(6):683-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is generally regarded as an opportunistic microorganism causing serious pneumonia in AIDS patients.
  • However, with the currently rising number of patients receiving immunosuppressive therapies for malignancies, allogeneic organ transplantations and autoimmune diseases, Pneumocystis pneumonia is becoming more and more recognized in non-HIV immunosuppressed individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. Antifungal Agents / therapeutic use. Pneumocystis jirovecii / isolation & purification. Pneumonia, Pneumocystis / diagnosis. Pneumonia, Pneumocystis / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521896.001).
  • [ISSN] 1744-8336
  • [Journal-full-title] Expert review of anti-infective therapy
  • [ISO-abbreviation] Expert Rev Anti Infect Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 184
  •  go-up   go-down


66. Ben M'barek L, Fardet L, Mebazaa A, Thervet E, Biet I, Kérob D, Morel P, Lebbe C: A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology; 2007;215(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.
  • BACKGROUND: Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies.
  • Several studies have suggested its interest for treating AIDS-related Kaposi's sarcoma.
  • OBJECTIVES: This study aimed to assess the efficacy and toxicity of thalidomide, an antiangiogenic agent, for the treatment of non-HIV-related Kaposi's sarcoma.
  • CONCLUSIONS: Our results show a true although modest interest of thalidomide in non-HIV-related Kaposi's sarcoma and prompt us to evaluate less toxic thalidomide analogues for this indication.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • [CommentIn] Dermatology. 2007;215(3):171-2 [17823510.001]
  • (PMID = 17823515.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


67. Pagès F, Galon J, Karaschuk G, Dudziak D, Camus M, Lazar V, Camilleri-Broët S, Lagorce-Pagès C, Lebel-Binay S, Laux G, Fridman WH, Henglein B: Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood; 2005 Feb 15;105(4):1632-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) latently infects and immortalizes B lymphocytes and causes lymphoproliferative malignancies.
  • We report that EBNA2 expression is associated with IL-18R expression in vivo in EBV-positive B-lymphomas from AIDS patients.
  • [MeSH-minor] Burkitt Lymphoma / immunology. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / virology. Cell Line, Transformed. Cell Line, Tumor. Gene Expression Regulation, Viral / immunology. Genes, Viral. Herpesvirus 4, Human / genetics. Humans. Interleukin-18 Receptor alpha Subunit. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / im